Genomma Lab Internacional, S.A.B. de C.V.
GNMLF
$0.83
-$0.03-3.49%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -1.73% | -5.89% | -10.35% | -6.20% | -1.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.73% | -5.89% | -10.35% | -6.20% | -1.91% |
| Cost of Revenue | -1.24% | -4.31% | -7.00% | -5.57% | -2.91% |
| Gross Profit | -2.01% | -6.80% | -12.23% | -6.57% | -1.33% |
| SG&A Expenses | -0.59% | -6.97% | -13.99% | -6.52% | -2.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 79.41% | 9.53% | 12.90% | -271.40% | -165.69% |
| Total Operating Expenses | -0.58% | -5.73% | -10.82% | -7.15% | -3.70% |
| Operating Income | -5.91% | -6.50% | -8.60% | -2.59% | 5.21% |
| Income Before Tax | -6.65% | -19.82% | -20.44% | -11.50% | 14.82% |
| Income Tax Expenses | -7.58% | -8.81% | -2.16% | -14.72% | 6.08% |
| Earnings from Continuing Operations | -6.23% | -24.17% | -27.38% | -9.96% | 19.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -658.30% | -658.30% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.17% | -0.94% | -1.45% | -36.20% | -10.15% |
| EBIT | -5.91% | -6.50% | -8.60% | -2.59% | 5.21% |
| EBITDA | -5.26% | -5.49% | -7.77% | -0.11% | 7.58% |
| EPS Basic | 27.01% | -3.79% | -5.83% | -38.62% | -11.63% |
| Normalized Basic EPS | -7.47% | -20.93% | -22.56% | -15.73% | 11.29% |
| EPS Diluted | 27.01% | -3.79% | -5.83% | -38.62% | -11.63% |
| Normalized Diluted EPS | -7.47% | -20.93% | -22.56% | -15.73% | 11.29% |
| Average Basic Shares Outstanding | 1.10% | 1.42% | 2.90% | 4.39% | 3.02% |
| Average Diluted Shares Outstanding | 1.10% | 1.42% | 2.90% | 4.39% | 3.02% |
| Dividend Per Share | -45.50% | -13.48% | -19.34% | 207.39% | 73.91% |
| Payout Ratio | 0.42% | 0.04% | -0.02% | 0.39% | -0.29% |